Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
22.55 USD +3.73% Intraday chart for Dianthus Therapeutics, Inc. +4.35% +116.83%
May. 16 HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target MT
May. 10 Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
AQ
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
AQ
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
AQ
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. News Dianthus Therapeutics, Inc.
  5. Press Releases